In addition, gene mutation analysis revealed that 50% of KMT2A-PTD mutated AML samples (AML#2, AML#3), 50% of NRAS mutated AML samples (AML#2, AML#3), and 67% of U2AF1 mutated MDS/AML samples (MDS#2, AML#3) were sensitive towards talazoparib and APE1 inhibitor III, respectively. This evidence concerns the gene NRAS and acute myeloid leukemia.